Top Stories
Deep Origin identified multiple small-molecule hits against a novel target in under three months, which BioAge validated in its lab.
ImmunityBio's therapy is now approved in adults with non-muscle invasive bladder cancer who have high-grade papillary-only tumours.
The agreement will see the companies discover and engineer three novel T-cell engagers utilising Vir's universal PRO-XTEN masking technology.
Yutrepia (treprostinil) can remain on the market for pulmonary arterial hypertension, but its pulmonary hypertension associated with interstitial lung disease indication will be removed.
The cuts — first reported by Belgian newspaper L'Echo — are expected to hit R&D, manufacturing and international support functions in the country.
Conference News
CAMBRIDGE, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today a...
Correction of MBNL- dependent mis-splicing provides functional evidence that SRP-1003 is degrading disease-causing RNA within the nucleus.In a preclinical model, SRP-1003 reduced pathogenic DMPK mRNA ...
Despite the remarkable progress made by ADCs, many cancer patients continue to face disease progression due to treatment resistance, tumor heterogeneity, and dose-limiting toxicitiesAt World ADC 2026 ...
Tamrada Theranostic Pair, 64Cu PET Imaging Agent and 177Lu Therapeutic Agent, Progressing to Clinical Trials64Cu-Tamrada Dosimetry Demonstrates 240-Fold Safety Factor for Planned First-in-Human StudyR...
CARSON CITY, Nev., Oct. 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodeg...
